Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation

v2.4.0.6
Share-based compensation
 9 Months Ended
Apr. 30, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

Note 4 – Share-based compensation


The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations:


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended
April 30,

 

Nine months ended
April 30,

 

 

 

2012

 

2011

 

2012

 

2011

 

 

 

 

 

 

 

Cost of clinical laboratory services

 

$

3

 

$

2

 

$

8

 

$

8

 

Research and development

 

 

1

 

 

6

 

 

4

 

 

16

 

Selling, general and administrative

 

 

164

 

 

216

 

 

583

 

 

846

 

 

 

 

 

 

 

 

 

$

168

 

$

224

 

$

595

 

$

870

 

 

 

 

 

 

 


No excess tax benefits were recognized during the nine month periods ended April 30, 2012 and 2011.


Stock option plans


A summary of the activity relating to the Company’s stock option plans for the nine month period ended April 30, 2012 is as follows:


 

 

 

 

 

 

 

 

 

 

 

 

 

Options

 

Weighted
Average
Exercise Price

 

Aggregate
Intrinsic Value

 

 

 

 

 

 

Outstanding at July 31, 2011

 

 

785,124

 

$

14.53

 

$

—

 

 

 

 

 

 

 

 

 

 

Exercised

 

 

—

 

 

—

 

 

 

 

Cancelled

 

 

(9,549

)

$

17.67

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding and exercisable at end of period

 

 

775,575

 

$

14.49

 

$

—

 

 

 

 

 

 

 

 


As of April 30, 2012, there were no unvested stock options.


Restricted Stock Awards


A summary of the activity pursuant to the Company’s restricted stock awards for the nine months ended April 30, 2012 is as follows:


 

 

 

 

 

 

 

 

 

 

Awards

 

Weighted
Average
Award Price

 

 

 

 

 

Unvested at July 31, 2011

 

 

311,952

 

$

4.84

 

Awarded

 

 

140,143

 

$

2.53

 

Vested

 

 

(95,516

)

$

5.61

 

Forfeited

 

 

(8,250

)

$

4.41

 

 

 

 

 

Unvested at end of period

 

 

348,329

 

$

3.71

 

 

 

 

 


The fair value of a restricted stock award is determined based on the closing stock price on the award date. As of April 30, 2012, there was approximately $0.8 million of unrecognized compensation cost related to unvested restricted stock-based compensation to be recognized over a weighted average remaining period of one and a half years.


The total number of shares available for grant as equity awards is approximately 2,678,000 as of April 30, 2012.